Zelgen Pharmaceuticals (688266)
SSE · 688266
Market Cap$23.8B
Revenue$1.5B
Employees1055
Listed OnSSE
Ticker688266
CEO / ExecMr. Zelin Sheng
HeadquartersKunshan
MarketMainland China
Websitewww.zelgen.com
Overview
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate and high-risk myelofibrosis. It also develops drug candidates in the NDA, Phase III, or registration
Data Note
This record combines exchange-directory fields with selected profile enrichment. Treat market data, leadership and financial figures as directional unless verified against company filings, exchange announcements or the issuer's own disclosures.